Anavex Lf SC Cm (AVXL) 6.94 $AVXL
5 Best-Performing Biotech Stocks of June
Arpita Dutt - Zacks Investment Research - Tue Jul 05, 2:28PM CDT
These 5 biotech stocks managed to beat the downward trend and shot up more than 20% in the month of Jun 2016.
XBIT: 14.78 (+0.28), OPXA: 4.25 (+0.06), AVXL: 6.94 (+0.64), TTHI: 1.57 (+0.02), XNCR: 18.54 (-0.30)
Buy 5 Attractive Biotechs at Bargain Prices
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 11:07AM CDT
Amid the recent wave of consolidations, it makes sense to zero in on some low-priced biotechs below $10 carrying a Zacks Rank #1 (Strong Buy) or Zacks Rank #2 (Buy).
MACK: 5.62 (-0.08), ARGS: 5.75 (-0.01), IDRA: 1.64 (+0.02), AVXL: 6.94 (+0.64), AVEO: 0.93 (-0.01)
Anavex Life Sciences (AVXL) in Focus: Stock Rises 16.4%
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 7:25AM CDT
Anavex Life Sciences Corp. (AVXL) moved big last session, as its shares jumped over 16% on the day.
AVXL: 6.94 (+0.64), INVA: 11.38 (-0.02)
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 6.94 (+0.64), ANIP: 58.12 (+0.59), RTRX: 18.30 (-0.19), ACOR: 25.65 (-0.13)
Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
GlobeNewswire - Wed Jun 22, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's Office of Orphan Product Development has granted Orphan Drug Designation to ANAVEX 2-73 for the treatment of infantile spasms.
AVXL: 6.94 (+0.64)
Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 15.04 (-0.03), PACB: 7.33 (-0.09), AVXL: 6.94 (+0.64), PPHM: 0.38 (unch)
Market Has Not Yet Noticed Potential in Anavex Life Sciences (AVXL); Have You?
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:48AM CDT
Anavex Life Sciences is seeing solid earnings estimate revisions and has an impressive Zacks Rank but that is not yet reflected in its price
AVXL: 6.94 (+0.64)
Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive data of ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorders, being held June 5-10, 2016 in Mount Snow, VT.
AVXL: 6.94 (+0.64)
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
GlobeNewswire - Fri May 20, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's (FDA) Office of Orphan Product Development (OOPD) has granted Orphan Drug Designation (ODD) to ANAVEX 2-73 for the treatment of Rett syndrome.
AVXL: 6.94 (+0.64)
Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
GlobeNewswire - Wed May 18, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces today that treatment with ANAVEX 2-73 significantly reduced the number of spasms in an animal model with infantile spasms (epileptic spasms) in infant rats.
AVXL: 6.94 (+0.64)
Anavex Life Sciences reports 2Q loss
Automated Insights - Wed May 11, 6:15AM CDT
NEW YORK (AP) _ Anavex Life Sciences Corp. (AVXL) on Wednesday reported a loss of $2 million in its fiscal second quarter.
AVXL: 6.94 (+0.64)
Anavex Reports Fiscal Second Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2016.
AVXL: 6.94 (+0.64)
Could a Pill to Cure Alzheimer's Disease Become Available Soon?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 26, 3:22PM CDT
Image source: Anavex Life Sciences. Recently, two women in Melbourne with Alzheimer's disease found themselves able to complete complex tasks they haven't been capable of for some time. One woman found herself suddenly able to play the piano again,...
AVXL: 6.94 (+0.64)
4 Stocks That Are Making Huge Gains Today
ACCESSWIRE - Mon Apr 25, 9:45AM CDT
NEW YORK, NY / ACCESSWIRE / April 25, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Friday. TPUB, AVXL, NEOT and LGCY are on high breakout alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
LGCY: 1.65 (-0.04), TPUB: 13.96 (+0.17), AVXL: 6.94 (+0.64), NEOT: 0.96 (-0.06)
U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
GlobeNewswire - Fri Apr 08, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX 3-71 for the treatment of Frontotemporal dementia (FTD).
AVXL: 6.94 (+0.64)
Anavex Presents New Data on Preclinical Development of ANAVEX 3-71
GlobeNewswire - Mon Mar 14, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive preclinical data on sigma-1 agonist ANAVEX 3-71 (formerly AF710B). The results show a statistically significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71.
AVXL: 6.94 (+0.64)
Covered Call Alerts For Celldex Therapeutics, Anavex Life Sciences Corp, El Pollo Loco, First Solar, Dollar Tree and hundreds of other stocks Released By InvestorsObserver
PR Newswire - Fri Mar 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for CLDX, AVXL, LOCO, FSLR and DLTR.
FSLR: 44.34 (-4.79), DLTR: 94.63 (-0.23), AVXL: 6.94 (+0.64), CLDX: 4.65 (+0.02), LOCO: 12.85 (+0.06), WTW: 11.50 (-0.02)
Anavex Announces Two-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response Analysis at AAT Conference
GlobeNewswire - Thu Mar 10, 6:00AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company" (Nasdaq:AVXL) today announced that the Company has received the approval from the Ethics Committee in Australia to extend the ongoing Phase 2a Alzheimer's trial, which had been requested by patients and their caregivers. The trial extension is designed to allow participants who complete 52 weeks in PART B to roll-over into a new trial and continue taking ANAVEX 2-73 for an additional 104 weeks, providing an opportunity to gather extended safety and efficacy data. The trial is independent of the Company's planned larger Phase 2/3 double-blinded, placebo-controlled study of ANAVEX 2-73 in Alzheimer's disease.
AVXL: 6.94 (+0.64)
Identifying Future Exponential Growth in Biotech
ACCESSWIRE - Mon Mar 07, 8:01AM CST
LAS VEGAS, NV / ACCESSWIRE / March 7, 2016 / Investing in biotechnology, particularly micro and small cap biotech companies, is unlike any other industry or sector in the market. When investors do their due diligence on most companies, they generally look at balance sheets, revenues, earnings and earnings per share. When investing in biotech throw that out the window.
AVXL: 6.94 (+0.64)
5 Best-Performing Biotech Stocks of June
Arpita Dutt - Zacks Investment Research - Tue Jul 05, 2:28PM CDT
These 5 biotech stocks managed to beat the downward trend and shot up more than 20% in the month of Jun 2016.
XBIT: 14.78 (+0.28), OPXA: 4.25 (+0.06), AVXL: 6.94 (+0.64), TTHI: 1.57 (+0.02), XNCR: 18.54 (-0.30)
Buy 5 Attractive Biotechs at Bargain Prices
Zacks Equity Research - Zacks Investment Research - Tue Jul 05, 11:07AM CDT
Amid the recent wave of consolidations, it makes sense to zero in on some low-priced biotechs below $10 carrying a Zacks Rank #1 (Strong Buy) or Zacks Rank #2 (Buy).
MACK: 5.62 (-0.08), ARGS: 5.75 (-0.01), IDRA: 1.64 (+0.02), AVXL: 6.94 (+0.64), AVEO: 0.93 (-0.01)
Anavex Life Sciences (AVXL) in Focus: Stock Rises 16.4%
Zacks Equity Research - Zacks Investment Research - Fri Jul 01, 7:25AM CDT
Anavex Life Sciences Corp. (AVXL) moved big last session, as its shares jumped over 16% on the day.
AVXL: 6.94 (+0.64), INVA: 11.38 (-0.02)
Anavex's Lead Candidate Gets Orphan Drug Status Yet Again
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:22PM CDT
Anavex Life Sciences (AVXL) announced that ANAVEX 2-73 has been granted orphan drug status by the FDA for the treatment of infantile spasms.
AVXL: 6.94 (+0.64), ANIP: 58.12 (+0.59), RTRX: 18.30 (-0.19), ACOR: 25.65 (-0.13)
Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
GlobeNewswire - Wed Jun 22, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's Office of Orphan Product Development has granted Orphan Drug Designation to ANAVEX 2-73 for the treatment of infantile spasms. AVXL: 6.94 (+0.64)
Coverage of Biotechnology Equities - Pacific Biosciences of California, Peregrine Pharma, Dynavax Technologies and Anavex Life Sciences
PR Newswire - Fri Jun 10, 6:45AM CDT
On Thursday, June 09, 2016, the NASDAQ Composite ended the trading session at 4,958.62, down 0.32%; the Dow Jones Industrial Average edged 0.11% lower to finish at 17,985.19; and the S&P 500 closed at 2,115.48, down 0.17%. ActiveWallSt.com has initiated coverage on the following equities: Pacific Biosciences of California Inc. (NASDAQ: PACB), Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM), Dynavax Technologies Corporation (NASDAQ: DVAX), and Anavex Life Sciences Corporation (NASDAQ: AVXL). Learn more about these stocks by accessing their free trade alerts at:
DVAX: 15.04 (-0.03), PACB: 7.33 (-0.09), AVXL: 6.94 (+0.64), PPHM: 0.38 (unch)
Market Has Not Yet Noticed Potential in Anavex Life Sciences (AVXL); Have You?
Zacks Equity Research - Zacks Investment Research - Mon Jun 06, 7:48AM CDT
Anavex Life Sciences is seeing solid earnings estimate revisions and has an impressive Zacks Rank but that is not yet reflected in its price
AVXL: 6.94 (+0.64)
Anavex Announces Positive Preclinical Results with ANAVEX 2-73 in Fragile X - Autism-Related Disorders
GlobeNewswire - Mon Jun 06, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive data of ANAVEX 2-73 in an exploratory study in a Fragile X syndrome model presented at the Gordon Research Conference for Fragile X and Autism-Related Disorders, being held June 5-10, 2016 in Mount Snow, VT. AVXL: 6.94 (+0.64)
Anavex Announces U.S. FDA Orphan Drug Designation to ANAVEX 2-73 for the Treatment of Rett Syndrome
GlobeNewswire - Fri May 20, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reports the U.S. Food and Drug Administration's (FDA) Office of Orphan Product Development (OOPD) has granted Orphan Drug Designation (ODD) to ANAVEX 2-73 for the treatment of Rett syndrome. AVXL: 6.94 (+0.64)
Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
GlobeNewswire - Wed May 18, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, announces today that treatment with ANAVEX 2-73 significantly reduced the number of spasms in an animal model with infantile spasms (epileptic spasms) in infant rats. AVXL: 6.94 (+0.64)
Anavex Life Sciences reports 2Q loss
Automated Insights - Wed May 11, 6:15AM CDT
NEW YORK (AP) _ Anavex Life Sciences Corp. (AVXL) on Wednesday reported a loss of $2 million in its fiscal second quarter.
AVXL: 6.94 (+0.64)
Anavex Reports Fiscal Second Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today reported financial results for the three and six months ended March 31, 2016. AVXL: 6.94 (+0.64)
Could a Pill to Cure Alzheimer's Disease Become Available Soon?
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 26, 3:22PM CDT
Image source: Anavex Life Sciences. Recently, two women in Melbourne with Alzheimer's disease found themselves able to complete complex tasks they haven't been capable of for some time. One woman found herself suddenly able to play the piano again,...
AVXL: 6.94 (+0.64)
4 Stocks That Are Making Huge Gains Today
ACCESSWIRE - Mon Apr 25, 9:45AM CDT
NEW YORK, NY / ACCESSWIRE / April 25, 2016 / The Stock Expert is issuing a report on four stocks that are performing well this Friday. TPUB, AVXL, NEOT and LGCY are on high breakout alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
LGCY: 1.65 (-0.04), TPUB: 13.96 (+0.17), AVXL: 6.94 (+0.64), NEOT: 0.96 (-0.06)
U.S. FDA Grants Orphan Drug Designation to ANAVEX 3-71 for the Treatment of Frontotemporal Dementia
GlobeNewswire - Fri Apr 08, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ANAVEX 3-71 for the treatment of Frontotemporal dementia (FTD). AVXL: 6.94 (+0.64)
Anavex Presents New Data on Preclinical Development of ANAVEX 3-71
GlobeNewswire - Mon Mar 14, 6:00AM CDT
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer's disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced positive preclinical data on sigma-1 agonist ANAVEX 3-71 (formerly AF710B). The results show a statistically significant reduction in the rate of cognitive deficit, amyloid beta pathology and inflammation with the administration of ANAVEX 3-71. AVXL: 6.94 (+0.64)
Covered Call Alerts For Celldex Therapeutics, Anavex Life Sciences Corp, El Pollo Loco, First Solar, Dollar Tree and hundreds of other stocks Released By InvestorsObserver
PR Newswire - Fri Mar 11, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for CLDX, AVXL, LOCO, FSLR and DLTR.
FSLR: 44.34 (-4.79), DLTR: 94.63 (-0.23), AVXL: 6.94 (+0.64), CLDX: 4.65 (+0.02), LOCO: 12.85 (+0.06), WTW: 11.50 (-0.02)
Anavex Announces Two-Year Clinical Extension Study of ANAVEX 2-73 and Presents Phase 2a Dose-Response Analysis at AAT Conference
GlobeNewswire - Thu Mar 10, 6:00AM CST
Anavex Life Sciences Corp. ("Anavex" or the "Company"
(Nasdaq:AVXL) today announced that the Company has received the approval from the Ethics Committee in Australia to extend the ongoing Phase 2a Alzheimer's trial, which had been requested by patients and their caregivers. The trial extension is designed to allow participants who complete 52 weeks in PART B to roll-over into a new trial and continue taking ANAVEX 2-73 for an additional 104 weeks, providing an opportunity to gather extended safety and efficacy data. The trial is independent of the Company's planned larger Phase 2/3 double-blinded, placebo-controlled study of ANAVEX 2-73 in Alzheimer's disease. AVXL: 6.94 (+0.64)
Identifying Future Exponential Growth in Biotech
ACCESSWIRE - Mon Mar 07, 8:01AM CST
LAS VEGAS, NV / ACCESSWIRE / March 7, 2016 / Investing in biotechnology, particularly micro and small cap biotech companies, is unlike any other industry or sector in the market. When investors do their due diligence on most companies, they generally look at balance sheets, revenues, earnings and earnings per share. When investing in biotech throw that out the window.
AVXL: 6.94 (+0.64)
